This notice of funding opportunity (NOFO) will support hypothesis-driven basic, preclinical, and translational laboratory research studies that will elucidate immunometabolic alterations during HIV infection that increase risk of TB or HBV disease, with the goal of identifying key mechanism and pathways that can be leveraged for new therapeutic and diagnostic strategies.
Research topics of interest on HIV immunometabolism and increased risk to either TB or HBV include, but are not limited to:
Applicants are strongly encouraged to:
This is a new funding opportunity, so no history of funding is available.
Applications proposing the following will be considered non-responsive and will not be reviewed:
Institutes of higher education, nonprofits other than institutions of higher education, for-profit organizations, local governments, federal governments, and other organizations are eligible to apply. Entities must be capable of implementing the project. Non-domestic entities may apply and foreign components are allowed.
Applications are due on September 7, 2025; January 7, 2026; May 7, 2026; September 7, 2026; January 7, 2027; May 7, 2027; September 7, 2027; and January 7, 2028. Similar deadlines are anticipated annually thereafter.
Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.